Drug only requests are currently considered. Financial funding requests are not considered at this time.
Research Interest:
- Explore the effects of empagliflozin on Cardio-Renal-Metabolic systems in patients with and without T2DM
Investigator Initiated Studies (IIS)
The Boehringer lngelheim IIS Program is offered to all qualified academic and community-based scientists or consortia who are interested in independently proposing and conducting their own research. Boehringer lngelheim may provide financial support and/or drug product for an approved IIS. Boehringer lngelheim does not serve as the Regulatory Sponsor for IIS.
In general, IIS are not registrational studies and may be proof of concept or exploratory in nature. The budget for such studies should reflect fair market value for all costs, and cannot include direct salary support for the Principal Investigator.
Boehringer lngelheim requires Investigators to apply for support via an online application process. Investigator applications received through other means will not be considered for review.
While the research interests listed within the therapeutic areas are of focus to Boehringer Ingelheim, other novel research interests may be considered.
Cardiometabolism
Oncology
For drug only support, a submitted synopsis will be evaluated on an ongoing basis for strategic interest. Where interested, Boehringer Ingelheim will request a full proposal submission. All proposals will be reviewed on an ongoing basis; generally monthly.
For requests involving financial support, Boehringer Ingelheim will evaluate a synopsis application on an ongoing basis for strategic interest. Where interested, Boehringer Ingelheim will request a full proposal submission.
1. Tumors driven by dysregulation of ErbB family members other than EGFR (e.g., HER2, HER3, HER4) in squamous cell lung cancer
2. Non-T790M acquired resistance to 1st/2nd generation EGFR TKIs
3. Acquired resistance to 3rd generation TKIs following either first or second line use
4. Safety and efficacy of afatinib following immunotherapy-containing regiments in squamous cell lung cancer
5. Monotherapy treatment of patients with uncommon, non-resistant EGFR mutations
Established Products
Aspirin/extended-release dipyridamole IIS Objectives
Evaluate potential clinical and non-clinical investigations involving COVID-19 related matters including safety, clinical outcomes, antiviral effects, or antithrombotic benefits.
Respiratory
1. Role of LAMA or LAMA/LABA in COVID-19
- Evaluate potential clinical and non-clinical investigations involving LAMA or LAMA/LABA in COVID-19, including safety and clinical outcomes.
Immunology
- Studies investigating the natural course of the disease in patients with Generalized Pustular Psoriasis (GPP) and/or Palmoplantar Pustulosis (PPP) (including risk factors; predictors, triggers, frequency and impact of flares; systemic symptoms; mortality)
- Studies investigating pathogenesis of GPP and/or PPP
- Studies investigating incidence and/or prevalence of GPP and/or PPP
- Studies investigating frequency and impact of comorbidities in patients with GPP and/or PPP (including plaque psoriasis, psoriatic arthritis, arthro-osteoitis)
- Studies investigating management of patients with GPP and/or PPP, including treatment patterns, supportive and/or palliative care and/or interventions to support/increase adherence to treatments (e.g. home programs, nurse support, other innovative digital tools)
- Studies to identify diagnostic and prognostic biomarkers in GPP and/or PPP (e.g. genetic, molecular, clinical)
- Studies to support the development, evaluation and/or validation of tools that assess patient reported outcomes in patients with GPP and/or PPP
- Studies investigating potential effects of Spesolimab in extracutaneous complications of the disease (for example polyarthritis, neutrophilic cholangitis, etc.)
- Studies addressing natural course of the disease, pathogenesis, epidemiological and management aspects in the areas of Hidradenitis Suppurativa, Plaque Psoriasis, Atopic Dermatitis, and/or other neutrophilic skin diseases
Biosimilars/CNS
(Currently, proposals are not being accepted in this area at this time)
Cardiovascular
(Currently, proposals are not being accepted in this area at this time)